You are here

Share:

Product Type

Development Stage

Therapeutic Area

Institutes and Centers

Search Technologies

Showing 1-20 of 309 results found

Synthetic Bacterial Nanoparticles as Drug and Vaccine Delivery Vehicles

Engineered bacterial spores can provide many useful functions such as the treatment of infections, use as an adjuvant for the delivery of vaccines, and the enzymatic degradation of environmental pollutants. Researchers at the National Cancer Institute’s Laboratory of Molecular Biology have developed a novel, synthetic spore husk-encased lipid bilayer (SSHEL) particle that is uniquely suited for a variety of these functions. NCI seeks partners to license and/or co-develop this technology toward commercialization.
  • Therapeutics
  • Vaccines
  • Devices

Method for HLA LOH Detection in Liquid Biopsies

The National Cancer Institute (NCI) seeks research co-development partners for a companion diagnostic (CDx) that detects human leukocyte antigen (HLA) loss-of-heterozygosity (LOH) and other biomarkers to predict efficacy of TCR-T cell adoptive transfer, immune checkpoint inhibition (ICI), tumor infiltrating lymphocytes (TIL), and other TCR-mediated immunotherapies.
  • Diagnostics

New T-Cell Immunotherapy that Targets Aggressive Epithelial Tumors

Researchers at the National Cancer Institute’s Experimental Transplantation and Immunology Branch (NCI ETIB) developed a T Cell receptor that specifically targets the Kita-Kyushu Lung Cancer Antigen 1 (KK-LC-1) 52-60 epitope that is highly expressed by several common and aggressive epithelial tumor types.
  • Therapeutics

Monoclonal Antibodies and Immunoconjugates Directed to the Non-ShedPortion (“Stalk”) of Mesothelin are Excellent Candidates for Developing Therapeutic Agents

Antibodies that specifically recognize and bind to the unshed portion (“stalk”) of human mesothelin are strong therapeutic candidates because they maintain contact with the cancer cell for a longer duration than other anti-mesothelin antibodies that are currently available. The National Cancer Institute (NCI) has developed such antibodies that specifically recognize and bind to the stalk of human mesothelin with high affinity. The NCI seeks licensing and/or co-development research collaborations to advance the development and commercialization of these antibodies.
  • Therapeutics

IgG4 Hinge Containing Chimeric Antigen Receptors Targeting Glypican-1 For Treating Solid Tumors

Researchers at the National Cancer Institute have developed a glypican-1 (GPC1) chimeric antigen receptor (CAR)-T cells using short immunoglobin subclass 4 (IgG4) hinge sequences that are highly potent against GPC1-expressing tumors. NCI seeks research co-development partners and/or licensees to advance the development of GPC1-IgG4 hinge CARs for the treatment of pancreatic cancer and other GPC1-expressing tumors.
  • Therapeutics

Anti-Py1235-Met Immunological Binding Reagent as Cancer Diagnostic

This technology consists of highly specific rabbit monoclonal antibodies reactive with phosphorylated tyrosine located at amino acid 1235 in the human MET sequence. Binding to this pYl235 residue is independent of the phosphorylation of other tyrosines in the vicinity (1230 and 1234), does not cross-react with these nearby phosphotyrosine residues, and does not occur when Y1235 is unphosphorylated. Researchers at the NCI seek licensing and/or co-development research collaborations  to commercialize and develop a companion diagnostic for selective MET inhibitors.
  • Diagnostics

Anti-CD133 Monoclonal Antibodies as Cancer Therapeutics

Researchers at NCI developed a rabbit monoclonal antibody that recognizes the marker for CD133 and is useful in pharmacodynamic testing to inform targeted anti-cancer chemotherapy development and clinical monitoring. CD133 is a cell surface glycoprotein used as a marker and expressed in stem cells such as hematopoietic stem cells, endothelial progenitor cells and neural stem cells. The NCI seeks collaborative co-development or licensing partners for this technology.
  • Diagnostics
  • Therapeutics

T-Cell Therapy Against Patient-Specific Cancer Mutations

Scientists at the National Cancer Institute developed a method to identify T cells that specifically recognize immunogenic mutations expressed only by cancer cells. NCI seeks parties interested in collaborative research to co-develop or license T-cell therapy against cancer mutations
  • Therapeutics

T cell tuning molecules that modify the immune response to cancer cells

Researchers at the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) seek partners to collaborate on in vitro studies to validate these potential immunomodulators and to conduct in vivo studies in a murine cancer model to determine the effects of ligands (e.g., antibodies) to the proteins on the immune response to cancer cells. Preference will be given to responses received by March 31, 2016.
  • Therapeutics

Pages